[1]吴丹丹,裴丽丽,李冰艳,等.二甲双胍通过调控STAT3的表达抑制头颈部肿瘤转移机制的研究[J].南京师范大学学报(自然科学版),2019,42(01):107.[doi:10.3969/j.issn.1001-4616.2019.01.017]
 Wu Dandan,Pei Lili,Li Bingyan,et al.Metformin Inhibits the Metastasis of Head and Neck Cancerby Regulating the Expression of STAT3[J].Journal of Nanjing Normal University(Natural Science Edition),2019,42(01):107.[doi:10.3969/j.issn.1001-4616.2019.01.017]
点击复制

二甲双胍通过调控STAT3的表达抑制头颈部肿瘤转移机制的研究()
分享到:

《南京师范大学学报》(自然科学版)[ISSN:1001-4616/CN:32-1239/N]

卷:
第42卷
期数:
2019年01期
页码:
107
栏目:
·生命科学·
出版日期:
2019-03-20

文章信息/Info

Title:
Metformin Inhibits the Metastasis of Head and Neck Cancerby Regulating the Expression of STAT3
文章编号:
1001-4616(2019)01-0107-06
作者:
吴丹丹裴丽丽李冰艳吴 瑕
南京医科大学康达学院基础医学部,江苏 连云港 222000
Author(s):
Wu DandanPei LiliLi BingyanWu Xia
Kangda College of Nanjing Medical University,Department of Basic Medicine,Lianyungang 222000,China
关键词:
二甲双胍STAT3头颈部肿瘤IL-6
Keywords:
metforminSTAT3head and neck cancrIL-6
分类号:
739.91
DOI:
10.3969/j.issn.1001-4616.2019.01.017
文献标志码:
A
摘要:
探讨二甲双胍是否通过调控STAT3的表达抑制头颈部肿瘤的EMT和迁移. 在头颈部肿瘤686LN细胞株上给予二甲双胍处理,Western blot检测上皮-间叶样转化(EMT)相关蛋白的表达; 通过Transwell实验检测二甲双胍对头颈部肿瘤细胞迁移能力的影响; 在高转移特性的头颈部肿瘤细胞株和配对的低转移特性的细胞株上,检测STAT3蛋白表达; 用脂质体转染STAT3的小干扰RNA,检测头颈部肿瘤EMT相关蛋白的表达; 在686LN上给予IL-6处理或者给予二甲双胍处理或者同时给予IL-6和二甲双胍处理,检测STAT3蛋白和EMT相关蛋白表达; 以及通过Transwell实验检测二甲双胍对IL-6诱导的细胞迁移的影响. 结果显示,给予二甲双胍处理,抑制头颈部肿瘤的EMT,并且细胞迁移能力减弱. STAT3磷酸化和总蛋白在高转移特性的头颈部肿瘤细胞株高表达. 转染STAT3 siRNA抑制STAT3的表达可抑制头颈部肿瘤的EMT. 二甲双胍抑制IL-6介导的STAT3磷酸化水平升高,抑制IL-6诱导的EMT,同时二甲双胍抑制IL-6诱导的细胞迁移. 结论说明,二甲双胍抑制头颈部肿瘤EMT和细胞迁移,并且能抑制IL-6介导的STAT3磷酸化水平升高,其抑制头颈部肿瘤迁移作用机制可能与下调STAT3的磷酸化水平有关.
Abstract:
To study whether metformin can inhibit the epithelial-mesenchymal transition and migration of head and neck cancer by regulating the expression of STAT3. Metformin was given on the head and neck cancer 686LN cell line and Western blot was used to detect related protein of epithelial-mesenchymal transition(EMT). The effect of metformin on head and neck cancer cell migration was determined by transwell assay. Western blot anlaysis was used to detect the expression of STAT3 in a highly metastatic head and neck cancer cell line and a paired low metastatic cell line. STAT3 siRNA transfected in head and neck cancer to detect the effect of STAT3 on EMT. Western blot anlaysis was used to detect the expression of STAT3 and EMT related protein in 686LN cells treated with IL-6 or metformin. The effect of metformin on cell migration induced by IL-6 by transwell assay. The EMT and the cell migration ability were inhibited in 686LN cells treated with metformin. The expressin of STAT3 phosphorylation and total protein in high level in the highly metastatic head and neck cancer cell line. Transfection of STAT3 siRNA inhibited the expression of STAT3 could inhibit the EMT of head and neck cancer. Metformin inhibited IL-6 mediated STAT3 phosphorylation and inhibits IL-6 induced EMT,while metformin inhibited IL-6 induced cell migration. The results showed that,metformin inhibited EMT and cell migration,and can inhibit IL-6 mediated STAT3 phosphorylation in head and neck cancer,which inhibited the metastasis of head and neck cancer may be related to the downregulation of the phosphorylation level of STAT3.

参考文献/References:

[1] BAUR D M,KLOTSCHE J,HAMNVIK O P,et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort[J]. Metabolism:clinical and experimental,2011,60(10):1363-1371.
[2]CHEN T W,LIANG Y N,FENG D,et al. Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90[J]. Journal of BUON:official journal of the Balkan Union of Oncology,2013,18(1):51-56.
[3]朱智峰,梁琳琅. 二甲双胍对结肠癌细胞增殖、周期及凋亡的影响[J]. 中国医科大学学报,2012,41(2):51-56.
[4]薛知新,钟捷,赵丹瑜,等. 二甲双胍对AGS胃癌细胞生长侵袭的抑制作用[J]. 世界华人消化杂志,2010,18(19):1974-1978.
[5]SIVEEN K S,SIKKA S,SURANA R,et al. Targeting the STAT3 signaling pathway in cancer:role of synthetic and natural inhibitors[J]. Biochimica et biophysica acta,2014,1845(2):136-154.
[6]ZHANG X,ZHANG J,WEI H,et al. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes[J]. Oncology reports,2007,17(6):1377-1382.
[7]DARNELL J E. STATs and gene regulation[J]. Science,1997,277(5332):1630-1635.
[8]WANG X H,LIU B R,QU B,et al. Silencing STAT3 may inhibit cell growth through regulating signaling pathway,telomerase,cell cycle,apoptosis and angiogenesis in hepatocellular carcinoma:potential uses for gene therapy[J]. Neoplasma,2011,58(2):158-171.
[9]BOLLRATH J,PHESSE T J,VON BURSTIN V A,et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis[J]. Cancer cell,2009,15(2):91-102.
[10]KIUCHI N,NAKAJIMA K,ICHIBA M,et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene[J]. Journal of experimental medicine,1999,189(1):63-73.
[11]ASGEIRSSON K S,OLAFSDOTTIR K,JONASSON J G,et al. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer[J]. Cytokine,1998,10(9):720-728.
[12]杨佳华,刘颖斌,董平. 上皮间质细胞转化与肿瘤细胞侵袭转移的关系[J]. 中华医学杂志,2011,91(8):572-574.
[13]ZHAO Z,CHENG X,WANG Y,et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis[J]. PloS one,2014,9(4):e95884.
[14]KASTRITIS E,CHARIDIMOU A,VARKARIS A,et al. Targeted therapies in multiple myeloma[J]. Targeted oncology,2009,4(1):23-36.
[15]WU D,CHENG J,SUN G,et al. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma[J]. Oncotarget,2016,7(24):36539-36550.
[16]IWATSUKI M,MIMORI K,YOKOBORI T,et al. Epithelial-mesenchymal transition in cancer development and its clinical significance[J]. Cancer science,2010,101(2):293-299.
[17]BAILEY C J,TURNER R C. Metformin[J]. The New England journal of medicine,1996,334(9):574-579.
[18]SIKKA A,KAUR M,AGARWAL C,et al. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation[J]. Cell cycle,2012,11(7):1374-1382.

备注/Memo

备注/Memo:
收稿日期:2018-10-16.
基金项目:国家自然科学基金(30873099)、南京医科大学康达学院科研发展基金(KD2016KYJJZD005).
通讯联系人:吴丹丹,硕士,讲师,研究方向:肿瘤药理. E-mail:wutongchuhan@163.com
更新日期/Last Update: 2019-03-30